优化表达人乳头瘤病毒(HPV)16型E7的乳酸杆菌疫苗以诱导黏膜E7特异性IFNγ产生细胞
本研究优化表达HPV16 E7的干酪乳杆菌(L. casei)疫苗以诱导黏膜E7特异性免疫应答。E7特异性黏膜IFNγ产生细胞的诱导依赖于展示的E7剂量,但在超过0.3 μg/10^8细胞后饱和。内源性表达E7的新菌株IGMKK16E7展示E7量最优,其诱导E7特异性黏膜IFNγ产生细胞较原菌株高4倍。
要点
- E7特异性黏膜IFNγ产生细胞的诱导依赖展示的E7剂量,超过0.3 μg/10^8细胞后饱和。
- 内源性表达E7的干酪乳杆菌IGMKK16E7展示E7量最优。
- IGMKK16E7诱导E7特异性黏膜IFNγ产生细胞较原菌株高4倍。
核心结论
- 新系统提供了展示E7量最优且能诱导黏膜Th1免疫应答的表达E7的干酪乳杆菌。
研究设计与样本
- 研究比较了不同剂量HPV16 E7分子展示于干酪乳杆菌(L. casei)后诱导黏膜免疫应答的效果,并构建了内源性表达E7的新菌株IGMKK16E7。
主要发现
- E7特异性黏膜IFNγ产生细胞的诱导依赖于展示的E7剂量,但在超过0.3 μg/10^8细胞后饱和。
- IGMKK16E7展示E7量最优,其诱导E7特异性黏膜IFNγ产生细胞较原菌株高4倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic HPV vaccine is an agent to induce E7-specific Th1 immune responses to treat cervical neoplasia (CIN2-3). Our previous clinical trial has demonstrated that oral administration of HPV16 E7-expressing Lactobacillus casei (L. casei), GLBL101c, resulted in the regression of HPV16-related CIN3. Here we examined optimization of the E7-expressing L. casei for induction of the mucosal immune responses to E7. Various doses of HPV16 E7 molecule were displayed on the L. casei. Immunization with E7-bound L. casei showed the induction of E7-specific mucosal IFNγ-producing cells was dependent on displayed E7-doses but saturated beyond 0.3 μg/108 cells. A new agent, L. casei with endogenous expression of E7 (IGMKK16E7), showed the optimal amount of displayed-E7. Immunization with IGMKK16E7 demonstrated 4-fold higher induction of E7-specific mucosal IFNγ-producing cells when compared with the former one. Our new system provided the optimal E7-expressing L. casei for displayed-E7 amount and induction of mucosal Th1 immune response.
引用
- Komatsu A, Igimi S, Kawana K, et al. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells. Vaccine. 2018. PMID: 29735324. doi:10.1016/j.vaccine.2018.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。